Main obstacles standing in the way of innovation in public pharmaceutical institutions in Brazil

Authors

  • Marcus Vinícius Lima do Couto Instituto de Tecnologia em Imunobiológicos, Fundação Oswaldo Cruz (Bio-Manguinhos/Fiocruz), Rio de Janeiro, RJ Author
  • Aline Rodrigues Venâncio das Neves Instituto de Tecnologia em Imunobiológicos, Fundação Oswaldo Cruz (Bio-Manguinhos/Fiocruz), Rio de Janeiro, RJ Author
  • Ester Ribeiro de Figueiredo Instituto de Tecnologia em Imunobiológicos, Fundação Oswaldo Cruz (Bio-Manguinhos/Fiocruz), Rio de Janeiro, RJ Author
  • Larissa dos Santos da Silveira Medquímica Indústria Farmacêutica, uiz de Fora, MG Author
  • Luciana Veloso da Costa Instituto de Tecnologia em Imunobiológicos, Fundação Oswaldo Cruz (Bio-Manguinhos/Fiocruz), Rio de Janeiro, RJ Author
  • Wanise Borges Gouvea Barroso Instituto de Tecnologia em Fármacos, Fundação Oswaldo Cruz (Farmanguinhos/Fiocruz), Rio de Janeiro, RJ Author

DOI:

https://doi.org/10.3395/2317-269x.00592

Keywords:

Innovation, Official Laboratories, Pharmaceutical Industry

Abstract

Innovation in pharmaceutical industry means to discover something new with therapeutic properties. It is a fundamental demand of organizations to achieve success in the market, as it represents a competitive advantage. In general, many factors stand in the way of innovating companies, universities and research institutes. When we talk about the public sector, there are many challenges. This article aims at presenting some of the main obstacles faced by the Brazilian public pharmaceutical institutions negatively contributing to innovation: difficulties related to infrastructure; funding and purchasing processes; discrepancies between the pharmaceutical industry institutional goals and the Ministry of Health’s demands; the need to introduce quality requirements in early stages of research; and the focus on technology transfer processes as the only source for innovation. Challenges are many, but with mood and motivation, both by the involved professionals and by the Brazilian government - which must show willingness to seek strategies to modify the current scenario -, it will be possible to reach an innovation culture in Brazil.

Downloads

Download data is not yet available.

Author Biographies

  • Marcus Vinícius Lima do Couto, Instituto de Tecnologia em Imunobiológicos, Fundação Oswaldo Cruz (Bio-Manguinhos/Fiocruz), Rio de Janeiro, RJ

    Bio-Manguinhos

    Departamento de Garantia da Qualidade

  • Aline Rodrigues Venâncio das Neves, Instituto de Tecnologia em Imunobiológicos, Fundação Oswaldo Cruz (Bio-Manguinhos/Fiocruz), Rio de Janeiro, RJ

    Bio-Manguinhos

    Centro Integrado de Protótipos, Biofármacos e Reativos para diagnóstico

  • Ester Ribeiro de Figueiredo, Instituto de Tecnologia em Imunobiológicos, Fundação Oswaldo Cruz (Bio-Manguinhos/Fiocruz), Rio de Janeiro, RJ

    Bio-Manguinhos

    Departamento de Garantia da Qualidade

  • Larissa dos Santos da Silveira, Medquímica Indústria Farmacêutica, uiz de Fora, MG

    Departamento de Produção Farmacêutica de Sólidos

    Medquímica Indústria Farmacêutica

  • Luciana Veloso da Costa, Instituto de Tecnologia em Imunobiológicos, Fundação Oswaldo Cruz (Bio-Manguinhos/Fiocruz), Rio de Janeiro, RJ

    Bio-Manguinhos

    Departamento de Controle de Qualidade

    Laboratório de Controle Microbiológico

     

  • Wanise Borges Gouvea Barroso, Instituto de Tecnologia em Fármacos, Fundação Oswaldo Cruz (Farmanguinhos/Fiocruz), Rio de Janeiro, RJ

    Far-Manguinhos

    Núcleo de Inovação Tecnológica

Published

2016-05-31

Issue

Section

Debate

How to Cite

Main obstacles standing in the way of innovation in public pharmaceutical institutions in Brazil. (2016). Health Surveillance under Debate: Society, Science & Technology , 4(2), 2-7. https://doi.org/10.3395/2317-269x.00592

Similar Articles

11-20 of 173

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)